ANZ News
Also, annalise.ai has made key executive appointments to support its global expansion.
It has been approved as a prescription-only software-as-a-medical device in the US.
The company has received backing from the state government of Western Australia.
Also, I-MED will expand its deployment of 4DMedical's lung imaging tool across its network in Australia.
It has zoom, rotate, and annotate features to help specialists explain procedures to patients virtually.
The company has also launched a distribution unit in the United States.
Two variants of the Annalise CXR Edge products will be offered in Australia.
The AI platform can predict a person's risk of having a stroke or a heart attack in the next five years.
Their combined solution eliminates manual scheduling and paging.
The company develops a breakthrough device for detecting residual cancer tissues.